InSite Vision
Global Online Auction

Sale Details

• Auction Opens: July 30, 2019
• Auction Closes: August 01, 2019
• Asset Removal: August 5, 2019
• Sale Preview: July 29, 2019

Auctioneer Fee

• Buyers Premium: 18%

Featured Assets

Location(s) Info

Assets located in 965 Atlantic Ave, Alameda, CA 94501

InSite Vision Overview

InSite Vision is advancing new specialty ophthalmologic products for treatment of diseases affecting the front and back of the eye. The company has two commercial products based on its innovative DuraSite® platform approved for the treatment of bacterial eye infections, AzaSite® (azithromycin ophthalmic solution) 1%, marketed in the U.S. by Akorn, Inc., and Besivance® (besifloxacin ophthalmic suspension) 0.6%, marketed by Bausch & Lomb, a wholly owned subsidiary of Valeant Pharmaceuticals International. InSite Vision has a proprietary portfolio of clinical-stage product candidates, and has filed an NDA for BromSite™ (0.075% bromfenac) for the treatment of inflammation and prevention of pain associated with cataract surgery. InSite Vision currently plans to file an NDA with the FDA in 2017 for the commercial approval by the U.S. Food and Drug Administration (FDA) of DexaSite™ for the treatment of blepharitis. InSite Vision’s AzaSite Plus™ is advancing through Phase 3 clinical studies for the treatment of eye infections, and ISV-101 is in Phase 1/2 clinical development for dry-eye disease and inflammation.

Event Notifications

For more information about this sale:

• JC Menendez
• Project Manager
• (831) 229-0804
• [email protected]

State Compliance

1. Auctioneer/Auction Surety Bond Number 100178167

2. The auction is being conducted in compliance with Section 2328 of the Commercial Code, Section 535 of the Penal Code, and the provisions of the California Civil Code.

Additional Information

New auction dates: Over 100 new lots to be added